Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

An Ultra-faint Galaxy Candidate Discovered in Early Data from the Magellanic Satellites Survey

We report a new ultra-faint stellar system found in Dark Energy Camera data from the first observing run of the Magellanic Satellites Survey (MagLiteS). MagLiteS J0644−5953 (Pictor II or Pic II) is a low surface brightness (N 28.5 mag arcsec 1 1 2 within its half-light radius) resolved overdensity of old and metal-poor stars located at a heliocentric distance of 45 kpc 4 5 . The physical size ( r1 2 46 pc 11 15 ) and low luminosity ( M V 3.2 mag 0.5 0.4 ) of this satellite are consistent with the locus of spectroscopically confirmed ultra-faint galaxies. MagLiteS J0644−5953 (Pic II) is located 11.3 kpc 0.9 3.1 from the Large Magellanic Cloud (LMC), and comparisons with simulation results in the literature suggest that this satellite was likely accreted with the LMC. The close proximity of MagLiteS J0644−5953 (Pic II) to the LMC also makes it the most likely ultra-faint galaxy candidate to still be gravitationally bound to the LMC

The second data release of the survey of the MAgellanic stellar history (SMASH)

The Large and Small Magellanic Clouds (LMC and SMC) are the largest satellite galaxies of the Milky Way and close enough to allow for a detailed exploration of their structure and formation history. The Survey of the MAgellanic Stellar History (SMASH) is a community Dark Energy Camera (DECam) survey of the Magellanic Clouds using ~50 nights to sample over ~2400 deg2 centered on the Clouds at ~20% filling factor (but with contiguous coverage in the central regions) and to depths of ~24th mag in ugriz. The primary goals of SMASH are to map out the extended stellar peripheries of the Clouds and uncover their complicated interaction and accretion history as well as to derive spatially resolved star formation histories of the central regions and create a "movie"of their past star formation. Here we announce the second SMASH public data release (DR2), which contains all 197 fully calibrated DECam fields including the main body fields in the central regions. The DR2 data are available through the Astro Data Lab hosted by the NSF's National Optical-Infrared Astronomy Research Laboratory. We highlight three science cases that make use of the SMASH DR2 data and will be published in the future: (1) preliminary star formation histories of the LMC, (2) the search for Magellanic star clusters using citizen scientists, and, (3) photometric metallicities of Magellanic Cloud stars using the DECam u-band. © 2021. The American Astronomical Society. All rights reserved.Immediate accessThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at [email protected]

The rate of convergence of the augmented Lagrangian method for nonlinear semidefinite programming

10.1007/s10107-007-0105-9Mathematical Programming1142349-39

Glucose Intolerance

in pres